Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats.

Glutamatergic abnormalities have been associated with several psychiatric disorders, including schizophrenia and addiction. Group II metabotropic glutamate receptors were targeted to normalize glutamatergic disruptions associated with an animal model of schizophrenia, the phencyclidine model. An agonist of this group of receptors, at a dose that was without effects on spontaneous activity and corticolimbic dopamine neurotransmission, attenuated the disruptive effects of phencyclidine on working memory, stereotypy, locomotion, and cortical glutamate efflux. This behavioral reversal occurred in spite of sustained dopamine hyperactivity. Thus, targeting this group of receptors may present a nondopaminergic therapeutic strategy for treatment of psychiatric disorders.

[1]  J. Brotchie,et al.  Metabotropic glutamate receptor agonists inhibit endogenous glutamate release from rat striatal synaptosomes. , 1995, European journal of pharmacology.

[2]  G. Rosenbaum,et al.  Study of a new schizophrenomimetic drug; sernyl. , 1959, A.M.A. archives of neurology and psychiatry.

[3]  P. Slater,et al.  Frontal Cortical and Left Temporal Glutamatergic Dysfunction in Schizophrenia , 1989, Journal of neurochemistry.

[4]  Carol A. Tamminga,et al.  Subanesthetic Doses of Ketamine Stimulate Psychosis in Schizophrenia , 1995, Neuropsychopharmacology.

[5]  S. Nakanishi,et al.  Molecular diversity and functions of glutamate receptors. , 1994, Annual review of biophysics and biomolecular structure.

[6]  F. Benes,et al.  Increased density of glutamate-immunoreactive vertical processes in superficial laminae in cingulate cortex of schizophrenic brain. , 1992, Cerebral cortex.

[7]  D. Schoepp,et al.  LY354740 is a Potent and Highly Selective Group II Metabotropic Glutamate Receptor Agonist in Cells Expressing Human Glutamate Receptors , 1997, Neuropharmacology.

[8]  P. Conn,et al.  Metabotropic glutamate receptors in brain function and pathology. , 1993, Trends in pharmacological sciences.

[9]  J. Pin,et al.  Pharmacology and functions of metabotropic glutamate receptors. , 1997, Annual review of pharmacology and toxicology.

[10]  D. Javitt,et al.  Recent advances in the phencyclidine model of schizophrenia. , 1991, The American journal of psychiatry.

[11]  J. Krystal,et al.  Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. , 1994, Archives of general psychiatry.

[12]  Bita Moghaddam,et al.  Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex , 1997, The Journal of Neuroscience.

[13]  J. Olney,et al.  Glutamate receptor dysfunction and schizophrenia. , 1995, Archives of general psychiatry.

[14]  R. Petralia,et al.  The metabotropic glutamate receptors, MGLUR2 and MGLUR3, show unique postsynaptic, presynaptic and glial localizations , 1996, Neuroscience.

[15]  J. Stewart,et al.  MK‐801 increases locomotor activity without elevating extracellular dopamine levels in the nucleus accumbens , 1996, Synapse.

[16]  Joseph T. Coyle,et al.  The Glutamatergic Dysfunction Hypothesis for Schizophrenia , 1996, Harvard review of psychiatry.

[17]  D. Schoepp,et al.  In vivo inhibition of veratridine-evoked release of striatal excitatory amino acids by the group II metabotropic glutamate receptor agonist LY354740 in rats , 1997, Neuroscience Letters.

[18]  S. Narayanan,et al.  The role of dopamine and AMPA/kainate receptors in the nucleus accumbens in the hypermotility response to MK801 , 1993, Pharmacology Biochemistry and Behavior.

[19]  T. Robbins,et al.  The case of frontostriatal dysfunction in schizophrenia. , 1990, Schizophrenia bulletin.

[20]  H. H. Kornhuber,et al.  Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia , 1980, Neuroscience Letters.

[21]  S. Ögren,et al.  Phencyclidine- and Dizocilpine-Induced Hyperlocomotion Are Differentially Mediated , 1994, Neuropsychopharmacology.

[22]  Herbert Weingartner,et al.  NMDA Receptor Function and Human Cognition: The Effects of Ketamine in Healthy Volunteers , 1996, Neuropsychopharmacology.

[23]  M. Lyon,et al.  Stereotyped responding by schizophrenic outpatients: cross-cultural confirmation of perseverative switching on a two-choice task. , 1986, Journal of psychiatric research.

[24]  C. Tamminga,et al.  Schizophrenia and glutamatergic transmission. , 1998, Critical reviews in neurobiology.

[25]  Lerner Se,et al.  Perspectives: acute phencyclidine intoxication. , 1976 .

[26]  S. Iversen.  Interactions between excitatory amino acids and dopamine systems in the forebrain: implications for schizophrenia and Parkinson's disease. , 1995, Behavioural pharmacology.

[27]  D. Schoepp,et al.  Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors. , 1998, The Journal of pharmacology and experimental therapeutics.

[28]  D. Lovinger,et al.  Metabotropic glutamate receptor-mediated presynaptic depression at corticostriatal synapses involves mGLuR2 or 3. , 1995, Journal of neurophysiology.

[29]  C. Yamamoto,et al.  A metabotropic glutamate receptor agonist DCG-IV suppresses synaptic transmission at mossy fiber pathway of the guinea pig hippocampus , 1996, Neuroscience Letters.

[30]  W. Schmidt.  Behavioural effects of NMDA-receptor antagonists. , 1994, Journal of neural transmission. Supplementum.